newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31,